Your browser doesn't support javascript.
loading
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Kim, Stephanie I; Szeto, Andy H; Morgan, Katherine P; Brower, Blaine; Dunn, Mary W; Khandani, Amir H; Godley, Paul A; Rose, Tracy L; Basch, Ethan M; Milowsky, Matthew I; Whang, Young E; Crona, Daniel J.
Afiliación
  • Kim SI; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Szeto AH; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Morgan KP; Division of Practice Advancement and Experiential Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America.
  • Brower B; Department of Pharmacy, UNC Hospitals and Clinics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Dunn MW; Division of Oncology, Department of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Khandani AH; Division of Oncology, Department of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Godley PA; Division of Molecular Imaging and Therapeutics, Department of Radiology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Rose TL; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Basch EM; Division of Oncology, Department of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Milowsky MI; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Whang YE; Division of Oncology, Department of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Crona DJ; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
PLoS One ; 16(6): e0253021, 2021.
Article en En | MEDLINE | ID: mdl-34153052
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Protocolos de Quimioterapia Combinada Antineoplásica / Radio (Elemento) / Quimioradioterapia / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Protocolos de Quimioterapia Combinada Antineoplásica / Radio (Elemento) / Quimioradioterapia / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos